Switzerland's startup funding landscape is not one interchangeable pool of capital. A first-round software team, a university spinout and a medical-device company can need different investors, evidence and timelines. Compare the current investment proposition before the nearest office address.
This guide compares 16 Swiss-connected venture investment platforms and angel networks. It distinguishes first-round capital, science-led specialists, commercial growth and member-led angel investing, with official sources for the next fit check.
Choose a Swiss capital route
- First financing round: Founderful states a first-round proposition; Swiss Founders Fund describes pre-seed and seed. Compare the team's country and business fit rather than assuming the two share identical requirements.
- Swiss B2B technology with first revenues: Spicehaus makes both the Swiss-headquarters and technical B2B focus explicit.
- Scientific and technical differentiation: compare Redalpine, Verve, Alpana and ND Capital against their actual investment topics.
- Healthcare: VI Partners, Debiopharm, Privilège and Endeavour Vision serve different parts of the health and life-sciences landscape.
- Angel participation: SICTIC facilitates member investment; it is not a single fund making one institutional decision.
Compare 16 investor routes in Switzerland
Use provider type, stage and geographic connection together. An office address is not a promise of eligibility. Where the current source does not establish a precise entry stage, the table leaves that question open.
Swiss investor platforms and angel networks, researched October 29, 2026. Selected research directory, not a ranking. On small screens, scroll the table sideways to see every column.
| Investor or network | Provider type | Stage | Sector focus | Geographic connection |
|---|---|---|---|---|
| Founderful | Venture capital firm | First financing round | Technology; Swiss founder teams | Swiss venture firm with a Zurich office |
| Redalpine | Multi-stage venture investment adviser | Multi-stage; confirm relevant vehicle | Software and science | Swiss roots; pan-European approach |
| Serpentine Ventures | Venture asset manager | Confirm the specific vehicle's entry stage | Venture technology; vehicle-specific focus | Swiss venture asset manager |
| SICTIC | Angel investor network; not a fund | Seed-stage technology | Technology | Matches investors with Switzerland-based startups |
| Swiss Founders Fund | Early-stage venture firm and company builder | Pre-seed and seed | Industry agnostic | St. Gallen-based; states a global investment approach |
| Swisscom Ventures | Venture investment adviser | Confirm current fund and entry stage | Technology and digital transformation | Advises funds investing in Swiss and international startups |
| Verve Ventures | Deep-tech investment platform | Confirm current vehicle and stage | Energy and resources; computing; health and bio | Swiss-operated platform focused on European deep tech |
| VI Partners | Venture capital firm | Early-stage | Life sciences and B2B technologies | Switzerland and Europe |
| Debiopharm Innovation Fund | Strategic corporate venture fund | Investment-ready companies; confirm stage | Pharma R&D and cancer-care health technology | Swiss pharma group's fund with a global patient-care focus |
| Alpana Ventures | Venture capital firm | Confirm entry stage | Digital transformation and deep tech | Swiss VC; Switzerland, Europe and the US |
| Privilège Ventures | Early-stage venture investor | Early-stage | HealthTech; MedTech; longevity | Swiss investor focused on Switzerland and Europe |
| Spicehaus Partners | Venture capital firm | Early-stage; first revenues toward scale | B2B technology with technical differentiation | Companies headquartered in Switzerland |
| EquityPitcher Ventures | Venture capital firm | Across stages; confirm current entry point | Technology; B2B industry relevance | Zurich-based; states a cross-market approach |
| Endeavour Vision | Healthcare investment firm | Development and commercialization; confirm stage | Medical devices and digital health | Geneva-based; companies on both sides of the Atlantic |
| Session VC | Entrepreneur-led investment and operating platform | Tech-enabled growth companies; confirm entry stage | Technology-enabled businesses | Swiss legal entity in Rapperswil |
| ND Capital | Venture capital firm | Across stages; confirm relevant team | Life, physical and data sciences | Teams in Switzerland and the US; invests across Europe and the US |
Swiss presence is not the same as a Swiss-only mandate
Use three separate fields in the shortlist: where the investor operates, where it says it invests, and which company conditions apply. Founderful describes a Swiss founder focus; Spicehaus expressly asks for Swiss-headquartered companies; Swiss Founders Fund states a global approach. These are not contradictory descriptions. They are different mandates.
For cross-border investors, clarify which team owns the opportunity and whether the company needs a particular operating connection. Do not restructure a company or assume eligibility from a directory entry.
Translate research strength into investment evidence
A scientific result is not the whole commercialization case. Prepare a short evidence map: what has been demonstrated, what has only been simulated, who would buy the resulting product, and what the proposed financing would prove next.
- Computing or industrial technology: describe technical performance, integration constraints and the first deployment.
- Life sciences or medical devices: distinguish scientific, development, clinical and commercial milestones; do not present one as proof of the others.
- B2B software: separate customer conversations, pilots, paid use and repeatable revenue.
The investor's current portfolio helps generate questions. It does not prove that a competing company, a different modality or your stage fits.
Know who makes the investment decision
SICTIC's published process explicitly says its members invest directly and that SICTIC itself does not hold startup shares. That changes your preparation: an event selection starts investor conversations rather than closing a round. An investment adviser or platform also requires a vehicle-level question, while an entrepreneur-led operator-investor may propose a different working relationship from a pooled venture fund.
Before sending sensitive documents, identify the responsible legal entity, the recipient's role and the intended review process. Share only material the team is authorized to disclose.
Investor profiles and official routes
These profiles are a research aid, not a performance ranking. Read the current strategy and portfolio before sharing a deck. A public contact route does not establish that a firm has available allocation for your round.
Founderful
Venture capital firm. Swiss venture firm with a Zurich office. Its current proposition is to lead a founder team's first financing round. Compare that earliest-stage role with the later commercialization evidence a specialist may want; its campus activities are not a second fund to count.
Founderful: official investment information
Redalpine
Multi-stage venture investment adviser. Swiss roots; pan-European approach. The current site calls Redalpine an investment adviser and emphasizes the intersection of software and science. Ask which advised vehicle and team match the company's stage rather than treating every portfolio company as a current mandate.
Redalpine: official investment information · contact
Serpentine Ventures
Venture asset manager. Swiss venture asset manager. Its current site invites new founding teams and describes a venture asset-management proposition. Separate the manager from the relevant fund; a diabetes-focused portfolio example does not make every company eligible for every vehicle.
Serpentine Ventures: official investment information · Additional official strategy or location evidence
SICTIC
Angel investor network; not a fund. Matches investors with Switzerland-based startups. SICTIC explicitly does not invest itself or hold startup shares. Its members invest directly, and the published pitch process begins with screening and an investor event. A selection to pitch is not a financing commitment.
SICTIC: official investment information · Published startup pitch process
Swiss Founders Fund
Early-stage venture firm and company builder. St. Gallen-based; states a global investment approach. The current site describes both building and investing in companies. Use its public pitch route and explain why the founder team and business fit; the word Swiss in the name is not a Swiss-only eligibility rule.
Swiss Founders Fund: official investment information · Official pitch submission route
Swisscom Ventures
Venture investment adviser. Advises funds investing in Swiss and international startups. The current proposition is minority investments through advised funds for Swisscom and institutional investors. Distinguish a financing discussion from a commercial partnership with the telecom business; neither automatically provides the other.
Swisscom Ventures: official investment information · Contact
Verve Ventures
Deep-tech investment platform. Swiss-operated platform focused on European deep tech. Use the current three investment topics to identify the relevant team. The website's investor Apply button is not established here as a founder pitch form, so begin with the official investment information rather than joining an investor onboarding flow.
Verve Ventures: official investment information · Current investment topics and team · Additional official strategy or location evidence
VI Partners
Venture capital firm. Switzerland and Europe. Its current About and Contact pages state an early-stage technology and healthcare focus across Switzerland and Europe. Match the company's evidence to the appropriate life-sciences or B2B team before requesting a conversation.
VI Partners: official investment information · Published founder contact guidance · Additional official strategy or location evidence
Debiopharm Innovation Fund
Strategic corporate venture fund. Swiss pharma group's fund with a global patient-care focus. This is a specialist route for technology that changes pharmaceutical R&D or cancer care, not a general digital-health category. Explain the specific workflow, evidence and strategic relevance without assuming a commercial agreement follows an investment.
Debiopharm Innovation Fund: official investment information · Contact
Alpana Ventures
Venture capital firm. Swiss VC; Switzerland, Europe and the US. Its published thesis connects deep-tech solutions with innovative business models. Show the customer and deployment case as well as the science; being based in Switzerland is one relevant connection, not the whole investment case.
Alpana Ventures: official investment information · Contact
Privilège Ventures
Early-stage venture investor. Swiss investor focused on Switzerland and Europe. The current strategy is more specific than a generic technology label: health, medicine and longevity. Use that current focus when researching fit rather than an older broad-sector description.
Privilège Ventures: official investment information
Spicehaus Partners
Venture capital firm. Companies headquartered in Switzerland. Its current website calls for must-have B2B technology and a Swiss headquarters. Record the customer evidence and operating connection explicitly; an overseas sales office does not establish the headquarters condition.
Spicehaus Partners: official investment information · Submit your pitch
EquityPitcher Ventures
Venture capital firm. Zurich-based; states a cross-market approach. The published approach spans industries, markets and stages. Make the industry problem and commercial use case concrete; do not interpret its network proposition as guaranteed sales or customer introductions.
EquityPitcher Ventures: official investment information
Endeavour Vision
Healthcare investment firm. Geneva-based; companies on both sides of the Atlantic. Its current positioning centers on transformative healthcare technologies and commercialization. A science project and a commercial medical-device company can need different evidence; clarify the product, development milestone and financing stage.
Endeavour Vision: official investment information · Contact
Session VC
Entrepreneur-led investment and operating platform. Swiss legal entity in Rapperswil. The partners describe committing their own time and capital and taking an owner-operator approach. Ask about operating involvement, ownership expectations and the particular investment structure rather than assuming a conventional passive seed fund.
Session VC: official investment information · Additional official strategy or location evidence
ND Capital
Venture capital firm. Teams in Switzerland and the US; invests across Europe and the US. Formerly NanoDimension, this venture firm is distinct from a similarly named operating company. Its current thesis emphasizes converging sciences; explain the technical breakthrough and market path, then confirm the stage and transatlantic fit.
ND Capital: official investment information · Contact
A worked shortlist for a Swiss industrial-software spinout
Illustrative research exercise, not a recommendation. A Zurich-headquartered team has a working industrial-software product, two early paying customers and a technical milestone to finance. It is not developing a medical device.
Use the evidence to shorten the queue
| Candidate | Research decision | Question to resolve |
|---|---|---|
| Spicehaus | Research the Swiss B2B route | Does the technical advantage and first-revenue evidence match its current criteria? |
| Redalpine | Research the software/science intersection | Which advised vehicle and team match this financing stage? |
| SICTIC | Check the startup pitch process | Does the team meet the current Swiss technology criteria and event timing? |
| Debiopharm Innovation Fund | Hold unless a real specialist fit emerges | The example has not established pharma-R&D or cancer-care relevance. |
Four names become three research tasks and one documented hold. The purpose is a defensible next action, not a predicted investment outcome.
Copy your investor shortlist worksheet
Use one record for each investor and specific vehicle. Keep the source date beside your fit decision.
SWISS INVESTOR FIT CARD
Company + round: [one sentence; stage; milestone]
Swiss operating connection: [headquarters; team; evidence]
Provider + specific vehicle: [name; fund/network/adviser]
Technical and customer evidence: [demonstrated / assumed]
Mandate match: [stage; sector; geography + official URL/date]
Open question: [one unresolved condition]
Public founder route: [verified URL]
Decision + owner: [shortlist / ask / hold; person; next action]Research the shortlist with Aurora, Claude or Codex
Give your AI teammate company facts you are authorized to share. Ask for sourced comparisons and open questions, not automatic introductions or outreach.
Be my Swiss investor-research teammate.
Company: [product, stage, headquarters and permitted evidence]
Next financing milestone: [what the round should prove]
Candidates: [five names from this guide]
Check their current official strategies and public founder routes.
Separate Swiss office, investment mandate and company eligibility.
Distinguish funds, advisers and angel networks.
Return a table of fit evidence, source/date, open question and next step.
Do not invent check sizes, contacts, eligibility or commercial introductions.
Use only information I am authorized to share.
Prepare the research queue; do not contact or submit to anyone.Keep the resulting investor records, relationship context and next actions together in Finta. The investor-prospecting workflow covers the next execution step.
Methodology, research date and local guides
Research checked October 29, 2026 by the Finta Editorial Team with AI-assisted source review. We reconciled provider names from our existing city research and reviewed current official strategy, portfolio, location or founder-contact pages. Firms with multiple offices count once; angel networks count as networks, not one committed pooled fund. We distinguish local presence from investment mandate and company eligibility. We do not infer check sizes, investor returns, lead behavior or open allocation from a portfolio logo.
The national guide combines, rather than duplicates, the established Swiss city research. ND Capital is counted once under its current name, with NanoDimension retained only as an alias. SICTIC is explicitly a network. Current strategies take precedence over old broad-sector summaries; for example, Privilège's current health focus and Spicehaus's B2B/Swiss-headquarters criteria remain visible.
This is a selected research directory, not an exhaustive register or sponsored ranking. Confirm the current vehicle, team and process directly before relying on a fit decision.
Make the next fundraising step specific
Choose a small set of defensible matches, record the open question, and assign the next action. Use our investor-shortlist guide and warm-introduction guide to prepare the conversation. A longer list should make the research better, not turn into an indiscriminate mailing list.